The Team Behind the Pipeline
Drug development, immunology, and machine learning — brought together to build multispecific immunotherapies designed to keep working as cancer changes.
Dr. Simon Bornschein
Chief Executive Officer
Simon holds a PhD in immuno-oncology and has spent his career at the intersection of cancer immunology and cell therapy — leading CAR-T development at Celyad Oncology and engineered immune cell programmes at Quell Therapeutics. As CEO, he leads strategy, portfolio direction, and company building, with a focus on turning differentiated programmes into medicines that matter.
Dr. Yulia Lampi
Chief Scientific Officer
Yulia holds a PhD in Molecular and Cell Biology and brings deep expertise in protein and gene engineering from Aelin Therapeutics and Quell Therapeutics, where she developed engineered cell therapies designed to modulate immune response with precision. As CSO, she leads scientific strategy, multispecific format design, and programme progression from discovery through optimisation.
Dr. Nils Hammerla
Chief Technology Officer
Nils holds a PhD in Computer Science and brings 15 years of applied machine learning experience from leadership roles at Twitter and Babylon Health. As CTO, he leads the computational architecture of FORGE — using large-scale functional immune-cell data to improve multispecific design with every screening cycle.
Scientific Advisory Board
- Prof. Nikhil MunshiHaematologist · Multiple myeloma clinical expert
- Tobias RaumAntibody engineering · Multispecific T-cell engager design
- Ashley WardDrug development · Biotech strategy
Join the Team in Oxford
We are building a focused, high-bar team in Oxford. If you work in immunology, computational biology, protein engineering, or drug development and want to help build therapies that matter in the clinic, get in touch.